Fennec Pharmaceuticals Inc.
FRX.TO
TSX
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Net Income | 73.00% | 41.99% | -2,134.17% | -512.44% | -540.11% |
| Total Depreciation and Amortization | 100.00% | 100.00% | -- | -190.05% | -193.19% |
| Total Amortization of Deferred Charges | -72.54% | -65.79% | -59.12% | -0.75% | -23.24% |
| Total Other Non-Cash Items | 0.40% | 26.09% | 16.70% | -44.39% | 133.86% |
| Change in Net Operating Assets | 2.18% | 13.15% | -187.55% | -139.28% | -167.92% |
| Cash from Operations | 82.54% | 64.75% | -146.23% | -133.84% | -150.71% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -- | -- | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -49.82% | -49.82% | -49.82% | -- | -- |
| Issuance of Common Stock | 3,952.83% | 2,895.12% | 2,408.41% | 72.40% | -39.67% |
| Repurchase of Common Stock | -59.42% | -5.01% | 42.41% | 45.72% | -495.00% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -11.95% | 100.00% | 100.00% |
| Cash from Financing | 294.11% | 292.02% | 266.19% | -340.07% | -350.49% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 192.59% | 161.40% | -24.03% | -165.80% | -186.66% |